Ireland - Inggeris - HPRA (Health Products Regulatory Authority)

noridem enterprises limited - cisatracurium - solution for injection/infusion - 2 milligram(s)/millilitre - other quaternary ammonium compounds; cisatracurium

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

aurobindo pharma limited - atracurium besylate (unii: 40ax66p76p) (atracurium - unii:2gq1iry63p) - atracurium besylate 50 mg in 5 ml

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

attix pharmaceuticals inc - atracurium besylate (unii: 40ax66p76p) (atracurium besylate - unii:40ax66p76p) - atracurium besylate 25 kg in 25 kg

Ireland - Inggeris - HPRA (Health Products Regulatory Authority)

as kalceks - atracurium besilate - solution for injection/infusion - 10 milligram(s)/millilitre - other quaternary ammonium compounds; atracurium

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

sagent pharmaceuticals - atracurium besylate (unii: 40ax66p76p) (atracurium - unii:2gq1iry63p) - atracurium besylate injection is indicated, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. atracurium besylate is contraindicated in patients known to have a hypersensitivity to it. use of atracurium besylate from multiple dose vials containing benzyl alcohol as a preservative is contraindicated in patients with a known hypersensitivity to benzyl alcohol.

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

sagent pharmaceuticals - atracurium besylate (unii: 40ax66p76p) (atracurium - unii:2gq1iry63p) - atracurium besylate injection is indicated, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. atracurium besylate is contraindicated in patients known to have a hypersensitivity to it. use of atracurium besylate from multiple dose vials containing benzyl alcohol as a preservative is contraindicated in patients with a known hypersensitivity to benzyl alcohol.

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

meitheal pharmaceuticals inc. - atracurium besylate (unii: 40ax66p76p) (atracurium - unii:2gq1iry63p) - atracurium besylate injection is indicated, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. atracurium besylate is contraindicated in patients known to have a hypersensitivity to it. use of atracurium besylate from multiple dose vials containing benzyl alcohol as a preservative is contraindicated in patients with a known hypersensitivity to benzyl alcohol.

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

sandoz inc - cisatracurium besylate (unii: 80ys8o1mbs) (cisatracurium - unii:qx62kli41n) - cisatracurium besylate injection is indicated: limitations of use cisatracurium besylate injection is not recommended for rapid sequence endotracheal intubation due to the time required for its onset of action. risk summary the 10 ml cisatracurium besylate multiple-dose vials contain the preservative benzyl alcohol. therefore, if cisatracurium besylate is needed during pregnancy, consider using a benzyl alcohol-free formulation (i.e., 5 ml and 20 ml cisatracurium besylate single-dose vials). because benzyl alcohol is rapidly metabolized by a pregnant woman, benzyl alcohol exposure in the fetus is unlikely. however, adverse reactions have occurred in premature neonates and low birth weight infants who received intravenously administered benzyl alcohol-containing drugs [see contraindications (4), warnings and precautions (5.2), and use in specific populations (8.4)] . there are no available clinical trial data on cisatracurium use in pregnancy to evaluate a drug associated risk of major birth defects, miscarria

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

teva parenteral medicines, inc. - cisatracurium besylate (unii: 80ys8o1mbs) (cisatracurium - unii:qx62kli41n) - cisatracurium besylate injection is indicated: - as an adjunct to general anesthesia to facilitate tracheal intubation in adults and in pediatric patients 1 month to 12 years of age - to provide skeletal muscle relaxation in adults during surgical procedures or during mechanical ventilation in the icu - to provide skeletal muscle relaxation during surgical procedures via infusion in pediatric patients 2 years and older limitations of use cisatracurium besylate injection is not recommended for rapid sequence endotracheal intubation due to the time required for its onset of action. cisatracurium besylate injection is contraindicated in patients with known hypersensitivity to cisatracurium. severe anaphylactic reactions to cisatracurium have been reported [see warnings and precautions (5.4 )] . the use of 10 ml cisatracurium multiple-dose vials is contraindicated for use in pediatric patients less than 1 month of age and low birth-weight infants because the formulation contains benzyl alcohol [see warnings a

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

somerset therapeutics, llc - cisatracurium besylate (unii: 80ys8o1mbs) (cisatracurium - unii:qx62kli41n) - cisatracurium besylate injection, usp is indicated: - as an adjunct to general anesthesia to facilitate tracheal intubation in adults and in pediatric patients 1 month to 12 years of age - to provide skeletal muscle relaxation in adults during surgical procedures or during mechanical ventilation in the icu - to provide skeletal muscle relaxation during surgical procedures via infusion in pediatric patients 2 years and older limitations of use cisatracurium besylate injection, usp is not recommended for rapid sequence endotracheal intubation due to the time required for its onset of action. - cisatracurium besylate injection is contraindicated in patients with known hypersensitivity to cisatracurium. severe anaphylactic reactions to cisatracurium besylate injection have been reported [see warnings and precautions (5.4)] . - the use of 10 ml cisatracurium besylate injection multiple-dose vials is contraindicated for use in pediatric patients less than 1 month of age and low birth-w